Glycan excellence against cancer
About Us

Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany, with the help of Prof. Dr. Peter Seeberger and Dr. Oren Moscovitz.
We strive to develop novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs).


Alena Horn
Office Manager
Fausto Gomes, PhD
Scientist Cell Biology
Francesco Muraca, PhD
Head of Cell Biology
Gustavo Moreira, PhD
Head of Antibody and Protein Biochemistry
Kajo Wiest
Head of Finance & Administration
Prof. Matthias Ocker, MD
Head of Experimental Medicine
Peter Sondermann, PhD
Wiebke Winkler, PhD
Scientist Antibody Generation

Board of Directors

Dr. Klaus Schollmeier
Chairman of the Board
Dr. Alexander Ehlgen
Boehringer Ingelheim Venture Fund
Dr. Frank Hensel
High-Tech Gründerfonds
Ulrich Mahr
Max-Planck-Innovation GmbH
Dr. Peter Neubeck
Kurma Partners
Tim Brans
Karlheinz Schmeling
Creathor Ventures
Prof. Dr. Peter Seeberger
Max-Planck-Institute for Colloids and Interfaces


Tumor-Associated Carbohydrate Antigens (TACAs)

TACAs are attractive targets for novel immunotherapeutics against human cancers. Many TACAs are expressed during embryonic development but not under physiologic conditions in differentiated tissues. On tumors, in contrast, TACAs show very high expression levels, allowing to bring more therapeutic agents to the cancer cell.


Our pipeline comprises several first-in-class assets targeting different TACAs across multiple solid human cancers.
Assets in our pipeline are amenable to various treatment modalities, including antibody-drug conjugates, T cell engagers and others.


Jun 14 2024, 12:00
Oren Moscovitz Wins Prestigious Hermann Neuhaus Prize

Dr. Oren Moscovitz has been awarded €25,000 by the Max Planck Society for his promising research toward treatments and non-invasive diagnostics for cancer, which could potentially reduce overall cancer-related deaths. Moscovitz and his team exploit unique sugar patterns found on cancer cells and develop ultra-small antibodies from alpacas (known as nanobodies) that bind to these sugars.

Download document
Jun 11 2024, 13:34
Tacalyx extends seed round to €14M


Read the full press release here:

Download document
Apr 08 2024, 18:00

TCX-101, a novel antibody-drug conjugate targeting a tumor- associated carbohydrate antigen for the treatment of solid tumors

Download document

We are a growing team of highly motivated scientists. We endorse the biotech spirit of problem solving and let the best idea win. Being innovative and focused is key to have fast decisions and optimized solutions for our early pipeline.
Located in one of Berlin's prestigious science hubs, we offer a vibrant research environment at the forefront of antibody drug development.

Please follow the link for current job offers.
Unsolicited applications are welcome!


Tacalyx GmbH

Magnusstr. 11
12489 Berlin

Follow Us